Research
Hormonal
Higher fasting insulin levels and lower Sex Hormone-Binding Globulin (SHBG) levels causally increase the risk of PCOS, acting as key metabolic drivers of the syndrome.
Managing insulin resistance is crucial for PCOS prevention and management. High insulin and low SHBG are causal factors. Lifestyle interventions that improve insulin sensitivity (diet, exercise) can mitigate PCOS risk by addressing these metabolic drivers.
StrongSupportsHIGH confidence
Genetically determined body fat percentage... whole body fat mass... fasting serum insulin (OR 6.98, 2.02–24.13), and SHBG concentration (OR 0.74, 0.64–0.87) were all significantly associated with PCOS in a linear relation.
Why this rating
Mendelian Randomization provides strong causal evidence for these metabolic markers.
Source
Childhood, adolescent, and adulthood adiposity are associated with risk of PCOS: a Mendelian randomization study with meta-analysis
Laurence J. Dobbie et al. · Human Reproduction · 2023
DOI 10.1093/humrep/dead053
Meta-analysis · 71 studiesCited 72×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Excess body fat during childhood and adolescence causally increases the risk of developing Polycystic Ovary Syndrome (PCOS) in adulthood, independent of adult body size.Strong
- Adult obesity and overweight significantly increase the odds of PCOS, with adolescents showing even higher odds than adults for the same degree of adiposity.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →